Plasmanate
Biological
Grifols, S.A.
Total Payments
$382,839
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $382,839 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $382,839 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Placebo-Controlled, Double-Blind Pilot Study to Evaluate the Effect of GRF6021 on Intracellular Signaling Cascades in Blood Leukocytes and Postoperative Recovery Following Primary Hip or Knee Arthroplasty | Grifols, S.A. | $382,839 | 0 |
Top Doctors Receiving Payments for Plasmanate
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Palo Alto, CA | $382,839 | 3 |
Ad
Manufacturing Companies
- Grifols, S.A. $382,839
Product Information
- Type Biological
- Total Payments $382,839
- Total Doctors 0
- Transactions 3
About Plasmanate
Plasmanate is a biological associated with $382,839 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Grifols, S.A..
Payment data is available from 2021 to 2021. In 2021, $382,839 was paid across 3 transactions to 0 doctors.
The most common payment nature for Plasmanate is "Unspecified" ($382,839, 100.0% of total).
Plasmanate is associated with 1 research study, including "A Randomized, Placebo-Controlled, Double-Blind Pilot Study to Evaluate the Effect of GRF6021 on Intracellular Signaling Cascades in Blood Leukocytes and Postoperative Recovery Following Primary Hip or Knee Arthroplasty" ($382,839).